摩根斯坦利分析报告.pdf

Morgan Stanley Global Healthcare
Unplugged Conference
September 14, 2010
Safe Harbor Statement
This presentation contains forward-looking statements that are
subject to various risks and uncertainties. Future results could differ
materially from those described in these forward-looking statements
due to certain factors, . changes in business, economic and
competitive conditions, regulatory reforms, results of clinical trials,
foreign exchange rate fluctuations, uncertainties in litigation or
investigative proceedings, and the availability of financing. Fresenius
does not undertake any responsibility to update the forward-looking
statements contained in this presentation.
Morgan Stanley Global Healthcare Unplugged Conference, Fresenius SE, Investor Relations © Copyright, September 14, 2010 Page 2
Achieving Profitable Growth in Attractive Health Care
Segments
- Listed in Frankfurt (DAX) 100%
- Sales 2009: € bn Fresenius
- EBIT 2009: €2,054 m Biotech
Oncology and
Immunology Therapies
EBIT 2009: -€44 m
36% 100% 99% 77%
Fresenius Fresenius Fresenius Fresenius
Medical Care Kabi Helios Vamed
Dialysis Products, Infusion Therapy, IV Drugs, Hospital Operations Engineering and Services
Dialysis Care Clinical Nutrition, for Hospitals and
Medical Devices/ Other Health Care Facilities
Transfusion Technology
Sales 2009: US$11,247 m Sales 2009: €3,086 m Sales 2009: €2,416 m Sales 2009: €618 m
EBIT 2009: US$1,756 m EBIT 2009: €607 m EBIT 2009: €205 m EBIT 2009: €36 m
Fresenius Medical Care is fully consolidated in the financial statements of Fresenius SE
Morgan Stanley Global Healthcare Unplugged Conference, Fresenius SE, Investor Relations © Copyright, September 14, 2010 Page 3
Fresenius Group: Financial Results
Sales e1
H1/10 €7,686 m €1,118 m €302 m
Growth at constant
10% 12% 23%
currency rates
Growth at actual
11% 14% 26%
currency rates
e attributable to Fresenius SE and before special items du